Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity

Eosinophils and their mediators play a crucial role in various reactive states such as bacterial and viral infections, chronic inflammatory disorders, and certain hematologic malignancies. Depending on the underlying pathology, molecular defect(s), and the cytokine- and mediator-cascades involved, peripheral blood and tissue hypereosinophilia (HE) may develop and may lead to organ dysfunction or even organ damage which usually leads to the diagnosis of a HE syndrome (HES). In some of these patients, the etiology and impact of HE remain unclear. These patients are diagnosed with idiopathic HE. In other patients, HES is diagnosed but the etiology remains unknown — these patients are classified as idiopathic HES. For patients with HES, early therapeutic application of agents reducing eosinophil counts is usually effective in avoiding irreversible organ damage. Therefore, it is important to systematically explore various diagnostic markers and to correctly identify the disease elicitors and etiology. Depending on the presence and type of underlying disease, HES are classified into primary (clonal) HES, reactive HES, and idiopathic HES. In most of these patients, effective therapies can be administered. The current article provides an overview of the pathogenesis of eosinophil-associated disorders, with special emphasis on the molecular, immunological, and clinical complexity of HE and HES. In addition, diagnostic criteria and the classification of eosinophil disorders are reviewed in light of new developments in the field.


Phenotype and target expression profile of eosinophils in health and disease
Eosinophils express a unique composition of cell surface receptors relevant to adhesion, homing, and migration in tissues [4,5,[59][60][61][62][63][64][65][66][67][68][69]. Some of these receptors contribute to the transmigration of eosinophils across endothelial monolayers and thus to the homing of eosinophils and their precursor cells in tissues, which is critical for the development of tissue HE found in patients with HE-related organ damage. Eosinophils display the C3bi receptor (CD11b/CD18), leukocyte function antigen-1 (LFA-1 = CD11a/CD18), L-selectin, E-and P-selectin ligands, low levels of sialyl Lewis x, and intercellular adhesion molecules (ICAM) [59][60][61][62][63][64][65][66][67][68][69]. Moreover, eosinophils display leukosialin (CD43) and the leukocyteinvasion receptor CD44. Whereas selectins and their receptors are considered to mediate eosinophil rolling and tethering on vascular cells, integrins and other receptors cause firm binding of eosinophils to endothelial cells prior to transmigration into tissues. Various cytokines and peptides may promote the expression and/or function of adhesion antigens on eosinophils. By contrast, glucocorticosteroids and some of the antiinflammatory cytokines may block expression of adhesion receptors on eosinophils and thus adhesion of eosinophils and their transmigration into tissues [70,71]. On the other hand, glucocorticosteroids may even upregulate expression of certain homing receptors, like CXCR4 (receptor for SDF-1), on eosinophils [72].
Finally, eosinophils display a number of cell surface receptors for certain viruses and related antigens, including the corona virus receptors CD13 and CD147, the measles virus receptor CD46, and the Echo-/Coxackie virus receptor CD55 (DAF) ( Table 3 and Fig. 2) [59]. Once activated by cytokines, such as IFN-gamma or tumor necrosis factor alpha (TNF-alpha), eosinophils may display additional virus receptors, such as the rhinovirus receptor CD54 (ICAM-1) [80]. Whether eosinophils can serve as a reservoir for certain viruses or as effector cells of tissue damage following virus infection, such as SARS-CoV-2 infection, remains unknown. It is worth noting in this regard that tissue inflammation and tissue damage (lung) induced by certain corona viruses are sometimes resembling features of HES. On the other hand, however, HE is usually not seen in patients with SARS-CoV-2 infections.
Eosinophils can synthesize and release a number of specific cytotoxic effector proteins, including eosinophil cationic protein (ECP), eosinophil major basic proteins (MBP1 and MBP2), eosinophil peroxidase (EPO), and eosinophilderived neurotoxin (EDN) ( Table 4) [86,87]. These compounds and other molecules, such as the eosinophil-derived Chemotaxis, activation? Tie-2/TEK * In hematologic malignancies with HE where oncogenic mutant forms of PDGFR or FGFR are expressed by neoplastic (progenitor) cells, the differentiation of eosinophils is considered to be triggered primarily by these oncogenic mutant forms of PDGFR/FGFR PDGF platelet-derived growth factor, FGF fibroblast growth factor, PAF platelet-activating factor, IL interleukin, GM-CSF granulocyte/macrophage colony-stimulating factor, TGF transforming growth factor, IFN interferon, CCL chemokine ligand, CCR chemokine receptor, MCP monocyte chemotactic protein, VEGF vascular endothelial growth factor extracellular DNA traps, contribute to microbe killing and thus innate immune host defense [86][87][88]. These DNA traps produced by eosinophils may also contribute to thrombophilia that is often associated with HE. Eosinophils also produce and release Charcot-Leyden crystals (CLC) which consist of the eosinophil granule protein Galectin-10 and may contribute to type 2 immunity and tissue inflammation [89]. Finally, eosinophils produce a number of repair molecules that may be involved in tissue homeostasis after an inflammatory or toxic reaction in local tissue sites. Likewise, eosinophil-derived molecules may counteract or degrade vasoactive molecules such as histamine (eosinophil-derived histaminase). Concerning HE-related organ damage, little is known about the exact role each of the eosinophil-derived substances play in various disease contexts. It is generally appreciated that eosinophil-derived chemokines, cytokines, and mediators contribute to leukocyte recruitment, tissue inflammation, thrombosis, fibrosis, and subsequent tissue damage (Table 4). Eosinophil products known to mediate fibrosis and thrombosis by affecting endothelial cell and/or platelet function include among others, DNA traps, plasminogen activator inhibitors, and toxic proteins [87][88][89][90][91][92][93][94].
These eosinophil-derived mediators and cytokines may all act together to cause thrombophilia, tissue fibrosis, and thus organ dysfunction or even tissue damage in patients with HE/ HES in various contexts and pathologies.

Definition and classification of HE and HES
Eosinophilia can be divided into relative and absolute eosinophilia, slowly progressing versus suddenly occurring eosinophilia, transient versus persistent eosinophilia, and mild (up to 1500/μL) versus marked eosinophilia (>1500/μL). When eosinophilia is marked and persists for several months, the term blood HE is appropriate [7][8][9][10][11]95]. Blood HE may or may not be accompanied by tissue HE in various organ systems. The term tissue HE is less well defined than the term blood HE. In general, tissue HE is characterized by a marked increase in eosinophils and/or a substantial deposition of eosinophil-derived proteins, like MBP, in tissue sections in affected organs [6-11, 91, 96, 97]. In patients with chronic tissue HE, eosinophils usually undergo cell death and disappear in local sites after activation and release of their proteins, so that the predominant histological finding of tissue HE may be deposition of MBP and other eosinophil-derived proteins without eosinophil accumulations [91,96].
Based on the underlying etiology, several variants of HE have been defined [10,11]: a very rare hereditary (familial) variant (HE F ), HE of unknown significance (HE US ) where the cause and clinical impact of HE remain unknown, primary (neoplastic) HE (HE N ) where clonal (neoplastic) eosinophils are detected, and secondary, reactive HE (HE R ) where normal (activated, non-neoplastic) eosinophils expand in a reactive (often inflammatory) process (Table 5) [10,11]. In rare cases, HE R is induced by a neoplastic process such as a lymphoma, a gastrointestinal tumor, or a lung carcinoma. In most patients with HE R , HE may be induced by eosinotropic cytokines, like IL-5.
Patients with unexplained HE may be asymptomatic for several months or even years. As mentioned, these patients are classified as HE US (Table 5) [10,11]. In these patients, no underlying (neoplastic or non-neoplastic) disease and no HEinduced organ damage are detected. Several of these patients may develop signs and symptoms of eosinophil-mediated organ damage during follow-up. When HE leads to organ damage in such patients, the final diagnosis is "hypereosinophilic syndrome" (HES) [10,11].
Like HE, HES is also divided into distinct variants based on underlying etiologies: idiopathic HES (unknown etiology: HES US ), primary (neoplastic) HES with an underlying clonal myeloid or stem cell disorder (HES N ), and secondary (reactive) HES in which a related non-neoplastic or paraneoplastic condition is detected and is responsible for the expansion of (activated) eosinophils (HES R ) (Table 6) [10,11].
A number of special variants of HES have also been described. One is the so-called lymphoid variant of HES (HES-L) [98][99][100][101]. Although no solid diagnostic criteria are available, HES-L exhibits several features of (and may therefore be regarded as) reactive HES (HES R ). Typically, T lymphocytes Fig. 1 The effects of various cytokines on migration of neoplastic eosinophils. The eosinophil cell line EOL-1 carrying FIP1L1-PDGFRA was loaded in the upper chambers of a Boyden-type double-chamber system. The lower chambers were supplemented with control medium or medium containing recombinant human SDF-1ɑ (25 ng/ml), IL-5 (100 ng/ml), eotaxin (500 ng/ml), FGF-1 (100 ng/ml), FGF-2 (100 ng/ml), PDGF-AA (100 ng/ml), or PDGF-BB (100 ng/ml). After 4 h (5% CO 2 , 37°C), the numbers of viable migrated cells collected in the lower chambers were measured by flow cytometry. Results are expressed as percent of all viable cells (100% input) and represent the mean ± S.D. of 3 independent experiments. Asterisk (*), p < 0.05 compared to medium control. Abbreviations: SDF-1, stroma cell-derived factor; IL-5, interleukin-5; FGF, fibroblast growth factor; PDGF, platelet-derived growth factor in these patients exhibit an abnormal phenotype (such as CD3 − /CD4 + ). In most cases, a clonal T cell receptor rearrangement is found. The clinical course of patients with HES-L is often indolent without signs of progression. However, some of the patients may progress to an overt T cell lymphoma.
A number of organ systems may be affected in HES, including the heart, lung, skin, gastrointestinal tract, and the central nervous system [6][7][8][9][10][11][102][103][104]. A particularly devastating manifestation of HES is the thromboembolic state which may include stroke, intracavitary thrombi in the heart, and vascular (arterial and/or venous) thrombosis. In addition, endomyocardial fibrosis, chronic tissue inflammation, and ulcerations in the skin are often seen in patients with HES [6,10,11,[102][103][104]. Such HES-associated organ damage may develop in all variants of HES, independent of the underlying etiology.
Endomyocardial fibrosis and thrombus formation as well as cardiac arrest are also seen in patients with eosinophil-rich neoplasms carrying the FIP1L1-PDGFRA fusion gene or other PDGFR variants. Most of these patients respond well to imatinib and early treatment with this drug may prevent irreversible organ damage in these patients [105][106][107][108]. Therefore, it is of considerable importance to perform diagnostic investigations, including molecular studies, as early as possible and to start treatment with imatinib before irreversible organ damage develops.

Diagnostic evaluations, staging, and diagnostic algorithms
Initial investigations in patients with HE include a detailed case history, especially travel histories, food, and toxin exposures, and certain infections and infestations. In the case of a suspected helminth infection, stool examinations and serology tests should be performed [8][9][10][11]13]. In addition, bacterial and viral infections must be excluded or diagnosed by appropriate serology and molecular assessments [8][9][10][11]13]. When no causative infection, drug, or toxin can be identified, the patient is examined for the presence of allergic (atopic) diseases, chronic inflammatory diseases, blood cell disorders, and other neoplastic conditions [8-19, 109, 110]. It is also worth noting that HE may be caused by more than one trigger or underlying disease. Therefore, diagnostic evaluations in HE should always encompass all major etiologies.
In all patients with HE, detailed laboratory examinations are performed, including blood counts with differential counts, serum chemistry including a basal serum tryptase level, inflammation markers (including fibrinogen and CRP), autoantibodies, serum IgE, and vitamin B12 [10,11,109,110]. In those with a suspected hematologic disease, molecular screen parameters are applied, including assays detecting PDGFR-related fusion gene products, such as FIP1L1-PDGFRA, KIT D816V, JAK2 V617F, BCR-ABL1, and clonal T cell receptor rearrangement [10,11,[13][14][15][16][17][18]. When these parameters disclose negative results, next generation sequencing (NGS) and BM studies should be considered. BM investigations are also performed when these screens show a positive test-result or other signs and symptoms suggest that the patient is suffering from a hematopoietic neoplasm. In patients with suspected eosinophilic leukemia or other myeloid neoplasms, the underlying disease is diagnosed based on WHO criteria [10,11,[13][14][15][16][17][18][19]. Investigations in these patients include morphologic studies of eosinophils and other cell types on good-quality BM and blood smears (stained with Wright-Giemsa) and a BM core biopsy with histology and immunohistochemistry to define the number, distribution, and phenotype of myeloid (precursor) cells, mast cells, megakaryocytes, and other BM cells, and to document or exclude BM fibrosis and myelodysplasia. Additional examinations include a detailed flow cytometry analyses, conventional cytogenetics, and fluorescence in situ hybridization (FISH) and molecular CD13 CD26 CD147 EOL-1 PB Eosinophils  Anti-fibrinolytic and prothrombotic effects * The direct toxic effects of the eosinophil-derived mediators, proteins and enzymes are often directed against certain microbes such as bacteria (antimicrobial effects) but may also be directed against various physiologic cells, especially when the number of eosinophils and the concentrations of these eosinophil-derived compounds increase in tissues, which may lead to tissue damage and thereby HES ** Neoplastic eosinophils triggered by various PDGFR mutant forms express and release increased amounts of OSM, certain chemokines, and other microenvironmental cell regulators compared to normal blood eosinophils HE hypereosinophilia, IL Interleukin, GM-CSF granulocyte/macrophage colony-stimulating factor, TGF transforming growth factor, TNF tumor necrosis factor, OSM oncostatin M, PAF platelet-activating factor, PGE prostaglandin E, TX thromboxane, PAI-2 plasminogen activator inhibitor-2 studies, including PCR and NGS [10,11,[16][17][18]. PCR and FISH are required to detect certain fusion gene variants, such as FIP1L1-PDGFRA and the related CHIC2 deletion (by FISH) [10,11,[16][17][18]. In patients with suspected lymphoid HES, a detailed flow cytometric analysis of lymphocytes should be performed, with the aim to exclude or identify aberrant populations, such as CD3 − /CD4 + T cells which are often detected in the lymphoid variant of HES = HES-L [8][9][10][11][98][99][100][101].
In all patients with suspected HES, HE-induced organ damage should be documented by appropriate staging investigations, including physical examination with a detailed inspection of the skin, cardiologic assessments, measurements of serum troponins and pro B-type natriuretic peptide (proPNB), an electrocardiogram and echocardiogram, assessment of pulmonary function, chest X-ray, abdominal imaging, computed tomography, cardiac MRT and biopsy, and gastrointestinal examinations with endoscopic biopsy studies [6-13, 109, 110].  Underlying pathologic conditions and differential diagnoses Once HE has been diagnosed, its etiology must be determined and the question as to whether (or not) the patient is suffering from HES (HE-induced organ damage) has to be clarified. In most patients with HE, an underlying reactive condition or neoplastic disease will be diagnosed, leading to the provisional diagnosis HE R [10,11]. In rare cases, a familiar variant of HE is identified (Table 5). When no underlying disease, no positive family history, no organ damage, and no other related disease or syndrome associated with HE is detected, the provisional diagnosis HE US is appropriate [11]. A number of reactive conditions and underlying diseases can produce HE (Table 1). Specifically, reactive HE (HE R ) may develop not only in patients with an underlying parasitic, bacterial, fungal, or viral infection but also in patients with IgE-dependent or IgE-independent allergies and patients with chronic inflammatory (auto-immune-mediated) disorders. In a subset of these patients, a reactive HES (=HES R ) is diagnosed. In addition, HE R may be identified in cancer patients, for example in adenocarcinomas developing in the lung, cervix, or the gastrointestinal (GI). There are also a few hematological malignancies where eosinophilia is typically reactive in nature, such as in Hodgkin's lymphoma, T cell lymphomas, or B cell acute lymphoblastic leukemia.
Myeloid neoplasms that typically present with clonal/ neoplastic HE (HE N ) include Ph + CML, certain variants of AML, and advanced SM (Table 1) [10,11,[14][15][16][17][18][19]. Moreover, marked eosinophilia (and sometimes HE) may develop in MDS, MPN, and MDS/MPN overlap neoplasms, including chronic myelomonocytic leukemia (CMML). These neoplasms should be diagnosed and classified using WHO criteria [10,11,[14][15][16][17][18][19]. Based on these criteria, hematopoietic neoplasms producing eosinophilia are initially classified according to the presence or absence of certain gene variants, including abnormalities (mutant forms) of PDGFRA, PDGFRB, or FGFR1, or the PCM1-JAK2 fusion gene. When one of these genetic lesions is detected, the final histopathological and hematological diagnoses still need to be determined, since the underlying disease may be an acute leukemia, an eosinophil-rich chronic leukemia, a MPN, or a CMML [10,11,[14][15][16][17][18][19]. Additional gene variants that may be detected in patients with myeloid neoplasms and eosinophilia include, among others, ETV6-ABL1, STAT5B N642H, and JAK2ex13InDel. Both the type of molecular lesion and the type of underlying disease have prognostic and therapeutic implications. For example, most (chronic) hematopoietic neoplasms exhibiting the FIP1L1-PDGFRA fusion protein are responsive to treatment with imatinib [105][106][107][108] whereas this is not the case in patients with a FGFR1-mutated malignancy. Indeed the prognosis changes when the FIP1L1-PDGFRA+ neoplasm turns out to be an acute leukemia.
Another important aspect is lineage involvement. For instance, in patients with PDGFR variants, lymphoid involvement is rarely seen, while patients with FGFR1-mutated neoplasms with concomitant HE may present with a stem cell malignancy exhibiting lymphoid and myeloid involvement. The WHO classification also includes the category "chronic eosinophilic leukemianot otherwise specified" (CEL NOS) [14][15][16][17][18]. However, there are patients who present with a more acute form of an eosinophil leukemia. Therefore, the international cooperative study group on eosinophil disorders (ICOG-EO) proposed to delineate between acute eosinophilic leukemia (AEL) and chronic eosinophilic leukemia (CEL), based on the percentage of blast cells [11].
In patients with HE in whom eosinophils are ≥30% and blast cells are ≥20% of all nucleated (BM or blood) leukocytes, the diagnosis is AEL [11]. In patients with HE in whom eosinophils are ≥30% and blast cells are <20% of all nucleated (BM or blood) leukocytes, the diagnosis is CEL [11].
Finally, there are a number of organ-specific disorders and systemic syndromes defined by HE and HES or HES-like pathologies. Although these syndromes have been separated from the classical variants of HES, the clinical presentations and courses often resemble HES [11]. Organ-specific disorders include eosinophil inflammatory states, such as eosinophilic esophagitis, eosinophilic gastritis, eosinophil duodenitis, eosinophil colitis, eosinophilic pneumonia, and eosinophilic hepatitis. In most of these reactive conditions, the disease is triggered by certain eosinopoietic cytokines such as IL-3, IL-5, IL-13, or GM-CSF, and at least for eosinophilic esophagitis/gastritis, ingestion of certain foods can be a crucial trigger. Systemic (multi-organ) syndromes include, among others, episodic angioedema and eosinophilia (Gleich's syndrome), eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome = CSS), eosinophilia myalgia syndrome (EMS), Omenn syndrome, and the Hyper-IgE syndrome.
A detailed description of all these pathologies and syndromes is beyond the scope of this article. We refer the reader to the available literature. Gleich's syndrome is defined by recurrent angioedema, peripheral blood HE, and elevated polyclonal IgM [111][112][113]. In several of these patients, phenotypically abnormal (activated) T cells (CD4 + T cells with decreased CD3 expression) can be documented [101,113]. Based on this notion, the Gleich's syndrome is also regarded as special form or manifestation of HES-L. Typical features of EGPA/CSS are asthma, a necrotizing vasculitis, and eosinophilia [114][115][116]. In a subset of these patients, anti-neutrophil cytoplasmic antibodies (ANCA) are detected [114][115][116]. EMS is characterized by myalgia, neurologic symptoms, and skin exanthema. Epidemic cases of EMS have been reported. In these patients, exposure to L-tryptophan has been described [117][118][119]. Therefore, the condition has also been termed toxic oil syndrome [117][118][119]. Both Omenn syndrome and the Hyper-IgE syndrome are rare inherited immunodeficiency disorders accompanied by eosinophilia.

Contemporary management of patients with HE-related disorders
For patients with HE US and HE F with a stable (silent) clinical course, a wait-and-watch strategy may be chosen, provided that no signs or symptoms indicative of organ dysfunction or organ damage develop [10,11]. In fact, both HE US and HE F are provisional diagnoses and in both instances, a hematologic disease or reactive disease with or without organ damage may develop in the follow-up [8][9][10][11][12][13][14].
The reactive form of HE (HE R ) is best managed by treating and (if possible) eradicating the underlying disease or pathology [8-11, 105-109, 120-124]. When eradication is not possible, symptomatic therapy may be sufficient to control problems related to eosinophil activation and HE in these patients. In many of these patients, organ damage (=HES R ) can be prevented by administration of glucocorticosteroids and/or other anti-inflammatory drugs [8-11, 109, 120-124]. In patients with severe eosinophilic granulomatosis and polyangiitis (EGPA/CSS), additional drugs, such as cyclophosphamide, may be required. It is worth noting that corticosteroids can induce apoptosis in eosinophils and their precursor cells and also suppress synthesis of eosinophil-activating cytokines and chemokines in T lymphocytes and other cells. In patients with idiopathic HES and HES-L, glucocorticoids are also recommended. However, side effects of long-term glucocorticoid therapy may be a clinical challenge and may be dose-limiting. Glucocorticosteroid-sparing agents may help in these cases. Apart from conventional drugs, including hydroxyurea and IFN-alpha, the anti-IL-5 antibody mepolizumab has been shown to be a safe and effective corticosteroid-sparing agent in these patients and is the only biologic approved for the treatment of HES in the USA [125][126][127][128][129].
Most patients with primary (neoplastic) HE and HES are not responding to corticosteroids or other anti-inflammatory agents. In these patients, specific targeted drugs and/or (more) intensive therapies are required to bring eosinophil counts and HE under control [10, 11, 16-18, 107, 122-124, 128-132]. The classes and type of drugs are selected based on the underlying neoplasm, the molecular drivers detected, and the overall situation in each case. Therefore, it is essential to define the molecular defects and the target expression profiles in clonal cells and to establish the exact histomorphological diagnosis and the extent of organ involvement and organ damage in each case [8][9][10][11][12][13][14][15][16][17][18][19].
In patients with chronic, eosinophil-rich, neoplasms exhibiting FIP1L1-PDGFRA or other imatinib-sensitive PDGFR variants, imatinib is regarded standard first-line therapy [10, 11, 16-18, 105-109, 130-132]. Although most patients show a long-lasting response to 100 mg imatinib daily, a few patients require a dose of 200 or 400 mg per day. A very few patients develop resistant disease, often in the context of rare secondary mutations in FIP1L1-PDGFRA [107,[130][131][132][133][134]. For these patients and for imatinib-intolerant cases, other PDGFR-targeting drugs, such as sorafenib or midostaurin, should be considered provided that the disease still presents as a chronic PDGFR-dependent neoplasm. Alternatively, these patients are treated with hydoxyurea or more intensive therapy, and the same holds true for patients in whom the disease progresses into an acute resistant leukemia. In some of these resistant patients, intensive chemotherapy and stem cell transplantation have to be considered. Patients with an advanced JAK2-mutated disease, including cases with JAK2 V617F and those with PCM1-JAK2, JAK-targeting drugs, such as ruxolitinib or fedratinib, may be considered. In patients with FGFR1-mutated chronic neoplasms with HE, treatment options are limited. In some of these patients, transient responses to midostaurin (in a ZNF198-FGFR1+ disease) or ponatinib (in BCR-FGFR1+ leukemia) have been described. However, in most patients, no long-lasting effects are seen. For patients with FGFR-mutated neoplasms, several FGFR-targeting drugs, such as pemigatinib, have recently been developed and are currently tested in clinical trials. However, most of these patients have drug-resistant disease and progress rapidly, often in form of an aggressive stem cell disease or a leukemia/lymphoma syndrome (8p11 syndrome). For these patients, intensive poly-chemotherapy and allogeneic stem cell transplantation combined with specific targeted drugs may be a reasonable approach to consider. However, even such intensive therapies may not always lead to long-term disease control or cure in patients with the 8p11 syndrome.

Concluding remarks and future perspectives
Eosinophils are multifunctional effector cells of the immune system that are involved in host defense, tissue remodeling, and tissue repair. Once activated, eosinophils may release toxic substances that support host defense and may also cause tissue damage, especially in hypereosinophilic states. HE may develop in the context of various hematologic neoplasms and in certain reactive states. In all these patients, it is important to (i) document or exclude a related neoplastic or non-neoplastic disease, and to (ii) document or exclude the presence of HErelated organ damage which leads to the diagnosis of HES. Clinically, the most frequent and most important manifestations of HES are thromboembolic events. Several immunological, serological, molecular, and cytogenetic markers are available to establish the nature of the underlying condition and thus to define the variant of HE and HES. Independent of the underlying condition, patients with established HES should be considered for early therapeutic intervention. In those with secondary HES, treatment of the underlying disease is usually effective. In some of these patients, IL-5-targeting antibodies can control HE. In myeloid neoplasms harboring mutated variants of PDGFRA or PDGFRB, imatinib or other PDGFRtargeting TKI are usually effective to control HE and to avoid HES-related organ damage. Our increasing knowledge about the etiology of HE, and the development of more specific markers and therapeutic approaches, should markedly improve diagnosis, management, and prognosis of patients with eosinophil disorders.

Declarations
Competing interests The authors declare that they have no studyrelated specific conflicts of interest. The authors declare the following conflicts of interest outside of this project: P.V. received a research grant from Pfizer, Celgene, and Novartis, and consultancy-related honoraria from Novartis, Pfizer, Celgene, Blueprint, Incyte, Abbvie, AB Science, Accord, Alexion, Orphan Pharmaceuticals, and TLL The Longevity Labs. H.U.S. is a consultant for GlaxoSmithKline. A.R. received consultancy honoraria from Novartis, Incyte, GSK, Astra Zeneca, Blueprint, Celgene/BMS, and Abbvie. B.S.B. receives publication-related royalty payments from Elsevier and UpToDate. He receives remuneration for consulting services (Blueprint Medicine, Glaxo SmithKline, Sanofi/ Regeneron) and for serving on the scientific advisory board of Third Harmonic Bio. He also receives remuneration for serving on the scientific advisory board of Allakos, which he co-founded, and owns stock in Allakos. He is a co-inventor on existing Siglec-8-related patents and thus may be entitled to a share of royalties received by Johns Hopkins University during development and potential sales of such products. The terms of this arrangement are being managed by Johns Hopkins University and Northwestern University in accordance with their conflict of interest policies.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.